Analysts Suggest Impact of Drug Pricing Reforms Would be Limited

Despite a litany of complaints and concerns from the industry, the new US drug pricing reform passed by the Democrats would have a marginal impact on pharma, according to analysts from the Bank of America and UBS. The legislation will allow Medicare to set Part D prices for some medications, 10 by 2026 and 60 by 2029. In addition, the Centers for Medicare and Medicaid Services (CMS) will be able to negotiate part B prices.

According to Fraiser Kansteiner, “While the bill addresses some 64 million Americans enrolled in Medicare, it fails to account for the more than 150 million Americans and their families engaged with the private insurance market, Seeking Alpha notes.”

To read more, click here.

(Source: Fierce Pharma, August 15th, 2022)